Friday, April 3, 2026
24.8
C
Bengaluru
Hot topics
IMS Health Market Reflection Report for July 2016
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams
A great manager is not just a leader; they...
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Hot topics
India’s Hospital Acquisitions Surge: RCML’s Pratiksha Deal Signals Expansion and Industry Trends
The healthcare sector in India has entered a dynamic...
Can Medicines Inject the Vitamins Amazon is Missing?
How Amazon’s Healthcare Bet May Change Indian Diagnostics and...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Fifth Aniversary Issue
Digital in Pharma Special Issue with Digital Marketing Case Study on Janssen's Me Without Migraine patient awareness campaign.
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Newsletter
Get important news delivered directly to your inbox and stay connected!